Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.38 |
| ▸ | HMGCR | P04035 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032690 | 1.00 | TSHR (0.39) | TSHRPTPN7HMGCRTDP1PTGER3 | |
| SCHEMBL3703469 | 1.00 | TSHR (0.39) | TSHRPTPN7HMGCRTDP1PTGER3 | |
| SCHEMBL2482113 | 0.97 | TSHR (0.41) | TSHRPTPN7HMGCRTDP1PTGER3 | |
| SCHEMBL2481579 | 0.91 | TSHR (0.47) | TSHRTDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL20577392 | 0.91 | TSHR (0.47) | TSHRTDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3702598 | 0.89 | PTGER3 (0.40) | TSHRPTPN7HMGCRTDP1PTGER3 | |
| SCHEMBL2481165 | 0.87 | PTGER3 (0.40) | TSHRPTPN7HMGCRTDP1PTGER3 | |
| SCHEMBL3125935 | 0.87 | TSHR (0.42) | TSHRTDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL19418777 | 0.87 | PTGER3 (0.46) | PTPN7HMGCRTDP1PTGER3ALDH1A1 | |
| SCHEMBL15058855 | 0.84 | TSHR (0.54) | TSHRTDP1ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10287262-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-14 | — | — | US | disclosed |
| EP-3222612-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2376432-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | TSHR 2914/4885PTPN7 4686/4885HMGCR 1017/4885 |
| US-10287262-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | TSHR 2512/4885PTPN7 4527/4885HMGCR 1204/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | TSHR 2512/4885PTPN7 4527/4885HMGCR 1204/4885 |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | TSHR 2868/4885PTPN7 4638/4885HMGCR 1172/4885 |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | TSHR 2868/4885PTPN7 4638/4885HMGCR 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.